Latest News

BROOKLYN, Mich.  – Full of life and full of love. That’s who four year-old Jaxon Meschke is. “All my friends! I love mom. I love dad and baby brother,” said four-year old Jaxon. But it’s his perseverance that stands out to his parents Brian and Chelsea Meschke most. “He really...
EATONS HILL — An Eatons Hill family knows the daily battles of managing life with cystic fibrosis. Alison and Ben Perkin are the proud parents of four children, two of whom have cystic fibrosis (CF), the most common incurable genetic condition that substantially shortens life expectancy. Mrs Perkin said her...
CAMBRIDGE, Mass. & BEIJING – BeiGene (NASDAQ: BGNE; HKEX: 06160) announced positive results from a planned interim analysis of the Phase 3 ALPINE trial comparing BRUKINSA® (zanubrutinib) against ibrutinib in adults with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). BRUKINSA met the primary endpoint of the trial, demonstrating...
Digital communities have become support networks for patients of rare diseases, as well as professionals. They boost access to research, encourage advocacy, and aid evidence-gathering When Lucinda Andrews learned that her newborn son was only the 16th person in the world known to be diagnosed with an ultra-rare genetic disorder, she...
Coronary artery bypass surgery provides long-term benefits for children whose hearts and blood vessels are damaged by Kawasaki disease, Japanese researchers report in Circulation: Journal of the American Heart Association. Researchers followed 114 people for up to 25 years who had bypass surgery as children or adolescents (ages 1 to...
Tucson, Arizona — Critical Path Institute’s (C-Path) Duchenne Regulatory Science Consortium (D-RSC) is excited to announce the launch of a groundbreaking model-based Clinical Trial Simulator (CTS), specifically designed to improve design of efficacy studies for potential therapies for Duchenne muscular dystrophy (DMD). This pioneering Drug Development Tool is set to...